Control Of Haematological Cancers By Natural Killer Cells
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Haematological cancers affect the blood and lymphoid organs and are generally lethal. Therapies targeting the anti-tumour capacities of the immune system have shown promising results in cancer patients. Natural Killer (NK) cells are key players of anti-tumour immune responses. This project will provide a better understanding of NK cell-mediated control of haematological malignancies that will be directly applied to the design of new curative therapies for blood cancer patients.
The Role Of NK Cell Receptors In Tumor Immunity And Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$641,264.00
Summary
White blood cells lymphocytes have an important role to play in cancer immunity and the activity of some cancer therapies. Therapeutics that improve lymphocyte function in patient tumors are showing great promise. Yet, virtually nothing is known about one family of lymphocyte receptors that control function in cancer. Using relevant mouse models of cancer and patient tumors we now wish to assess the relative importance of this family of receptors in tumor immunity, therapy, and escape.
Targeting Human Dendritic Cells In A Multiple Myeloma Humanized NOD/SCID Model
Funder
National Health and Medical Research Council
Funding Amount
$425,696.00
Summary
Adoptively transferred dendritic cells (DC) loaded with tumor associated antigen (TAA) have been shown to induce anti-tumor immunity in animal models; however, their therapeutic efficacy in cancer patients has not been established. Protective immunity has failed in the tumor-bearing host and the ability of human DC to induce anti-tumor responses in the abnormal environment of the cancer patient requires further investigation. Due to the limited capacity to investigate the DC-tumor interaction in ....Adoptively transferred dendritic cells (DC) loaded with tumor associated antigen (TAA) have been shown to induce anti-tumor immunity in animal models; however, their therapeutic efficacy in cancer patients has not been established. Protective immunity has failed in the tumor-bearing host and the ability of human DC to induce anti-tumor responses in the abnormal environment of the cancer patient requires further investigation. Due to the limited capacity to investigate the DC-tumor interaction in patients, humanized animal models containing human DC and tumor provide an opportunity to obtain important new information. We propose to develop multiple myeloma (MM) as a human tumor in our humanized (hu)NOD-SCID model containing human DC, and to use this in vivo MM-huNOD-SCID model to restore immunity by correcting the human DC-tumor interaction.This knowledge will act as a fast track to select and design a new (simplified) DC-based immunotherapy to treat cancer patients and will be translated directly into our MM clinical trials program, potentially by targeting human DC based on CD205 recognition.Read moreRead less
We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells. We wish to learn how cancer can sometimes evade the immune system. Our work will also find out how some common treatments for cancer, like chemotherapy, can be used to boost the immune system and eliminate tumours. Through knowledge gained from these studies, we aim to develop new therapies that can help patients with devastating diseases like cancer.